Recovery Peptides

An endogenous cardiovascular peptide that signals through the APJ receptor, studied for heart failure, cardiac repair, and cardioprotection with multiple synthetic analogs in clinical development.

A non-erythropoietic EPO analog studied for nerve repair and neuropathic pain conditions.

A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties.

A combined formulation of BPC-157 and TB-500, the two most commonly paired tissue repair peptides.

A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions.

A growth hormone releasing hormone analog studied for stimulating growth hormone secretion.

A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification.

A synthetic hexapeptide growth hormone secretagogue studied for its potent stimulation of growth hormone release via the ghrelin receptor.

A growth hormone secretagogue that also stimulates appetite through ghrelin receptor activation.

A multi-peptide blend of BPC-157, TB-500, and GHK-Cu formulated for tissue repair and skin rejuvenation.

A modified form of IGF-1 with extended half-life, studied for muscle growth and tissue development.

A truncated form of IGF-1 with high potency and rapid local activity at the site of administration.

A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.

A multi-peptide blend combining BPC-157, TB-500, GHK-Cu, and KPV for comprehensive tissue repair and anti-inflammatory support.

A PEGylated splice variant of IGF-1 studied for muscle repair and satellite cell activation, with an extended half-life compared to native MGF.

A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.

A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment.

A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.

A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery.